Linsitinib - Sling Therapeutics
Alternative Names: ASP-7487; Linsitinib - Astellas Pharma; OSI-906; OSI-906AALatest Information Update: 13 Jun 2024
At a glance
- Originator OSI Pharmaceuticals
- Developer Astellas Pharma; Multiple Myeloma Research Foundation; Sling Therapeutics
- Class Cyclobutanes; Imidazoles; Pyrazines; Quinolines; Small molecules
- Mechanism of Action IGF type 1 receptor antagonists; Insulin receptor antagonists; Protein tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Graves ophthalmopathy
- Preclinical Autoimmune disorders; Unspecified
- Discontinued Adrenocortical carcinoma; Liver cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Osteosarcoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 11 Oct 2023 Sling Therapeutics initiates enrolment in a phase IIb/III extension trial for Graves ophthalmopathy in USA (PO) (NCT06112340)
- 25 Sep 2023 Pharmacodynamics data from preclinical study in Graves ophthalmopathy released by Sling Therapeutics